Adriana C. Gamboa et.al. conducted a study to assess the latest evidence guiding the histiotype‐specific management of extremity/truncal and retroperitoneal Soft‐tissue sarcomas with regard to surgery, radiation, and chemotherapy. The researchers concluded that continued collaborative efforts will allow studies to be both sufficiently large and sufficiently focused to generate evidence that is clinically meaningful in specific Soft‐tissue sarcomas patient populations.
Lucy Boyce Kennedy et.al. conducted a study to focus on the toxicities of checkpoint inhibitors and chimeric antigen receptor T cells, including pathophysiology, diagnosis, and management. The researchers concluded that cornerstone of toxicity management is often steroids or immunosuppression, and ongoing studies are evaluating the effect of immunosuppression on antitumor efficacy.
Jingjing Miao et.al. conducted a study to investigate the outcomes with a reduced primary clinical target volume and radiation dose for early-stage nasopharyngeal carcinoma. The researchers concluded that decreased primary clinical target volume margins and radiation doses can achieve long-term tumor control with mild late toxicities for patients with early-stage nasopharyngeal carcinoma.
E. G. Garcia et.al. conducted a study to identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-cell acute lymphoblastic leukemia. The researchers concluded that new roles for PRL3 as a collaborating oncogenic driver in human T-cell acute lymphoblastic leukemia and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-cell acute lymphoblastic leukemia.
A. Kuendgen et.al. conducted a study to assess if applying the WHO classification for p-myelodysplastic syndromes successfully predicts time to transformation and survival. The researchers concluded that classification tools established in p-myelodysplastic syndromes were effective for stratifying subgroups in t-myelodysplastic syndromes and indicated the high prognostic relevance of cytogenetics in t-myelodysplastic syndromes.
Chuangzhong Deng et.al. conducted a study to assess Tumor‐infiltrating immune cells as they play a crucial role in tumor progression and response to treatment. The researchers concluded that application of chemotherapy may activate the local immune status and convert OS into an immune “hot” tumor.
Matthias Guckenberger et.al. conducted a study to assess potential adaptations of radiotherapy in two pandemic scenarios. The researchers concluded that joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.
Ying Wang et.al. conducted a study in 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 29 with resolved HBV-infection (HBsAg negative and anti-HBc positive). Safety and efficacy were compared with 29 subjects without HBV-infection. The researchers concluded that chronic and resolved HBV-infection do not affect the safety and efficacy of CAR-T-cell therapy.
Kylee J. Veazey et.al. conducted a study to assess the effect of CARM1 inhibition in reducing histone acetyltransferase activity that causes synthetic lethality in CREBBP/EP300-mutated lymphomas. The researches concluded that CARM1i further reduces the histone acetyltransferase activity of CBP genome wide and downregulates CBP-target genes in DLBCL cells, resulting in a synthetic lethality that leverages the mutational status of CREBBP/EP300 as a biomarker for the use of small-molecule inhibitors of CARM1 in DLBCL and other cancers.
Ping Du et.al. conducted a study to assess the tumor killing effect of ceritinib plus PD‐L1 inhibitor in vitro by quantitative RT‐PCR, flow cytometry, ELISA, western blot analysis, PBMC coculture system, and plasmid and transfection experiments. The researchers concluded that Ceritinib and PD‐L1 inhibitor combined produced a synergistic antineoplastic efficacy in vitro and in vivo, which provides a key insight and proof of principle for evaluating CER plus PD‐L1 blockade as combination therapy in clinical therapeutic practice.